Nanchang Anobri Pharmaceutical CO., LTD – FDA 483, Nov 13, 2023
Nanchang Anobri Pharmaceutical CO., LTD, a drug product manufacturer in Nanchang City, Jiangxu, was cited for significant deficiencies across its quality, laboratory, material, production, facilities, equipment, design, audit, process validation, document, and personnel systems. Key issues include inadequate quality unit review, deficient HPLC peak integration, incomplete batch records, and insufficient validation and control procedures for both drug products and drug-device combination products. These findings indicate a broad lack of adherence to established procedures and regulatory requirements, potentially impacting product quality and data integrity.
ID · e6abb269-d7ab-4d54-b1d7-f126127d5e13
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.